AAIC 2016 showcases exciting Alzheimer's developments

1 August 2016

Progress in Alzheimer's treatment has been frustratingly slow and researchers have struggled to comprehend the mechanisms of a condition that varies greatly in severity and speed of progression.

Pharma has been rocked by costly late-stage failures, with many drugs showing promise in the lab, only to flop in large-scale clinical trials, and no new novel Alzheimer's therapeutic has been approved since Namenda (memantine) in 2003.

The rising prevalence of Alzheimer's - the most common dementia-causing disease - puts a huge strain on health and care systems, making effective treatments a priority. The World Alzheimer's Report of 2015 reveals that if global dementia care were a country, it would now be the world's 18th largest economy, on course to become a trillion dollar cost by 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK